Leuven, Belgium – September 11, 2017. Materialise NV (Nasdaq: MTLS) announced today that U.S. patients can now benefit from their patient-specific implants, 3D-printed in titanium for maxillofacial surgery. As the first 3D-printed titanium maxillofacial implants to receive clearance for the U.S. market, the decision marks a further extension to Materialise’s longstanding collaboration with DePuy Synthes, who will distribute the device in the U.S.
Materialise has partnered with winter sports gear and tailored footwear specialist Tailored Fits, to launch the world’s first end-to-end digital supply chain for custom-fit ski boots. The supply chain is supported by a customization platform for wearables, co-developed by Materialise and Tailored Fits, which includes a customer interface, design automation and process automation. Materialise also provides the entire production capacity for the certified additive manufacturing of the customized ski boots.
Total revenue increased 21.8% from the second quarter of 2016 to 33,612 kEUR, with increases in all three business segments.
Adjusted EBITDA increased 164% from 1,034 kEUR for the second quarter of 2016 to 2,732 kEUR.
Total deferred revenue from annual software sales and maintenance contracts amounted to 17,206 kEUR at the end of the second quarter of 2017 compared 16,799 kEUR at the end of the fourth quarter of 2016
Leuven, Belgium and Padua, Italy – July 20, 2017. The forward-looking made in Italy brand OXYDO goes eclectic, with the disruptive designs of the new OXYDO SS 2017 Collection. This launch marks the first offering from the partnership between Materialise NV (NASDAQ: MTLS), leader in Additive Manufacturing solutions and software, and Safilo Group, the Italian powerhouse behind numerous iconic eyewear brands worldwide. The new OXYDO Capsule Collection is an expression of intent, demonstrating not only what Additive Manufacturing is capable of today but where it could lead the eyewear industry tomorrow.
PLYMOUTH, MICH., June 13, 2017 – Cardiovascular medical device developers and clinicians are often required to conduct clinical trials for their devices and procedures to ensure they will perform safely and effectively across their patient population. Numerous medical professionals across the United States have partnered with Materialise, using the company’s 3D printing software and services to improve outcomes and efficiency in these extensive and often costly trials and help bring innovations to market.